N1BI34:BVMF
Neurocrine Biosciences Bdr
47,20Â BRL
arrow_downward
-1,56%(-0,75) 1d
19 de nov., 17:29:53 GMT-3 · BRL
search
Tots els sÃmbols
| SÃmbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadÃstiques principals per a N1BI34...
Obre
50,00Â BRL
Alt
50,00Â BRL
Baix
46,15Â BRL
Capitalització borsà ria
15,85Â kM
Volum mitjÃ
1,75Â k
Volum
0,00
Alt 52 setmanes
50,00Â BRL
Baix 52 setmanes
31,51Â BRL
Accions en circulació
101,22Â M
Nombre d'empleats
2Â k
Obre
50,00Â BRL
Alt
50,00Â BRL
Baix
46,15Â BRL
Capitalització borsà ria
15,85Â kM
Volum mitjÃ
1,75Â k
Volum
0,00
Alt 52 setmanes
50,00Â BRL
Baix 52 setmanes
31,51Â BRL
Accions en circulació
101,22Â M
Nombre d'empleats
2Â k
NotÃcies
De fonts web i partners de notÃcies
Investing.com Canada
·
fa 4 hores
Neurocrine Biosciences director Gary Lyons sells $2.47M in shares By Investing.com
Yahoo Finance
·
fa 1 dia
Neurocrine Biosciences (NBIX) Stock Still Looks Undervalued As Its 89% Run Draws Focus
Perfil
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Sobre Neurocrine Biosciences Bdr
Conseller delegatKevin C. Gorman
Empleats2,5Â k
Fundació1992
Seu principalSan Diego, Califòrnia, Estats Units d'Amèrica
SectorHealth Care
Sector-
Lloc webneurocrine.com